

PRESS RELEASE FOR IMMEDIATE RELEASE

PHARMANIAGA, CSPC JOIN FORCES TO ADVANCE BIOPHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION

SHAH ALAM, 26 July 2023 – Pharmaniaga Berhad (Pharmaniaga) and CSPC Pharmaceutical Group Limited (CSPC) of China today forged a partnership on the research and development, manufacturing, and commercialisation of innovative pharmaceutical and biopharmaceutical products.

The collaboration was sealed via a Memorandum of Understanding (MoU) signed by Pharmaniaga LifeScience Sdn Bhd (PLS) and CSPC Holdings Company Limited that underscores the mutual dedication of both parties to enhance the production of CSPC's biopharmaceutical portfolio, focusing on its advanced mRNA vaccines, leading towards the commercialisation of these products in Malaysia and other relevant territories.

Malaysian Investment Development Authority (MIDA) Chief Executive Officer Datuk Wira Arham Abdul Rahman lauded the strategic collaboration. "This collaboration holds the promise of propelling Malaysia towards becoming a vaccine-producing country within the ASEAN region."

He further added, "This MoU aligns with the strategic objectives of the National Investment Aspirations (NIA), New Industrial Master Plan (NIMP), and National Vaccine Development Roadmap (NVDR) blueprint, fostering the production of pharmaceutical and bio-pharmaceutical products to achieve national self-sufficiency level, hence reducing dependency on importation of these products."

Pharmaniaga Executive Committee (EXCO) Chairman Ahmad Shahredzuan Mohd Shariff said, "We are exploring to leverage on CSPC's mRNA technology platform for vaccine development, and CSPC is a proven and reliable partner in this endeavour.

"The MoU strengthens the pre-existing relationship between Pharmaniaga and CSPC. Pharmaniaga currently acquires the Active Pharmaceutical Ingredient (API) for Azithromycin Dihydrate (antibiotics used to treat various bacterial infections) from CSPC," he said.

Pharmaniaga's R&D team views CSPC's mRNA technology platform as having significant potential, especially in the development of vaccines for diseases like the flu, respiratory syncytial virus, zoster, HPV, and dengue.

The collaborative interests of Pharmaniaga and CSPC go beyond vaccines, venturing into various pharmaceutical products within the realms of anti-infective, cardiovascular, neurology, gastroenterology, immunology, and pulmonary treatments. This holistic approach promises to ensure the partnership's versatility and far-reaching impact, catering to a wide array of healthcare requirements.



The alliance also includes the collection of market data to assess the commercial viability of CSPC's innovative pharmaceutical products in key therapeutic sectors such as anti-tumour, cardiovascular, and neurology.

-END-

About Pharmaniaga Berhad

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of the Company. Listed on the Main Board of Bursa Malaysia, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy. With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and is empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical arena. For more information, please log on to https://pharmaniaga.com/

Issued for Pharmaniaga Group by Corporate Communication Division, Pharmaniaga Berhad. For media enquiries, please contact Dato' Zuhri Iskandar Kamarzaman at 03- 3342 9999 ext 434 or email zuhri@pharmaniaga.com.